Gritstone Oncology Inc.
News
Gritstone bio Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Simply Wall St Gritstone bio ( NASDAQ:GRTS ) Second Quarter 2024 Results Key Financial Results Revenue: US$921.0k (down 53% from 2Q...\n more…
GRTS Stock Earnings: Gritstone Bio Beats EPS, Misses Revenue for Q2 2024
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nGRTS stock results show that Gritstone Bio beat analyst estimates for earnings per share but missed on revenue for the second quarter of...\n more…
Gritstone bio Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Globe Newswire -- Preliminary randomized Phase 2 data suggest GRANITE (personalized neoantigen vaccine) could drive meaningful clinical benefit in front-line metastatic microsatellite-stable colorectal cancer...\n more…
GRITSTONE ALERT: Bragar Eagel & Squire, P.C. is Investigating Gritstone bio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Globe Newswire NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Gritstone bio, Inc. (NASDAQ...\n more…
GRTS Investors Have Opportunity to Join Gritstone bio, Inc. Fraud Investigation with the Schall Law Firm
Business Wire The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gritstone bio, Inc. (Gritstone or the Company) (NASDAQ: GRTS...\n more…
GRTS Investors Have the Opportunity to Lead Gritstone bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR Newswire GRTS Investors Have the Opportunity to Lead Gritstone bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm GRTS Investors Have the Opportunity to Lead Gritstone bio, Inc. Securities Fraud...\n more…